Navigation Links
Generex Biotechnology to Make Presentations At 46th Annual Meeting,of the European Society of Pediatric Endocrinology

WORCESTER, Mass., Jun 27, 2007 (PrimeNewswire via COMTEX News Network) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it will be making three poster presentations at the 46th Annual Meeting of the European Society of Pediatric Endocrinology in Helsinki, Finland June 27 -- 30, 2007 (www.espe2007.org).


The three abstracts feature Generex Oral-lyn(tm), the Company's proprietary oral insulin spray product, including a study in juveniles. The Company previously announced that it is preparing for a Phase 3 clinical trial of Generex Oral-lyn in centres in the United States, Europe, and Canada. The abstracts are:

6-Month Study on the Safety and Efficacy of Oral Insulin (Generex Oral-lyn(tm)) Administered at Lunchtime in Juvenile Type-1 DM Subjects Maintained on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin, by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador, together with Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs;

Comparison Of Metabolic Control Of Pre-Prandial S.C. Regular Insulin Versus Prandia Oral Insulin (Generex Oral-lyn(tm)) In Adult Type-1 DM Subjects Maintained on Basal S.C. BID Isophane Insulin (NPH), by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador; and

Near Normalization of Metabolic Control in Type-1 DM Using Conventional Insulin Therapy and a 13-Point Method Designed to Enhance Compliance, by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador, together with Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs.

The European Society for Paediatric Endocrinology (ESPE) is an international organization with several hundred members from over 45 countries whose aim is to promote the highest levels of knowledge, research, education, and clinical practice of paediatric endocrinology and metabolism throughout the world. Founded in 1962, ESPE has increased in both size and scope, becoming one of the largest and most leading international scientific communities of paediatric endocrinologists.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at http://www.generex.com. Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications , potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Generex Biotechnology Corp.

Generex
Shayne Gilliatt
800-391-6755
416-364-2551

CEOcast, Inc.
Andrew Hellman
212-732-4300



'"/>




Related medicine technology :

1. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
3. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. Prana Biotechnology Presents New Key Findings on PBT2
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
7. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
8. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
9. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... their offering. ... The global chromatography market to grow at a ... Market 2016-2020, has been prepared based on an in-depth market analysis with ... growth prospects over the coming years. The report also includes a discussion ...
(Date:12/8/2016)... , December 8, 2016 ... "Sugar-Based Excipients Market by Product (Actual Sugars, Sugar ... (Filler & Diluent, Tonicity Agents), Formulation (Oral, Topical, ... MarketsandMarkets, the market has witnessed healthy growth during ... at a CAGR of 4.3% between 2016 and ...
(Date:12/8/2016)... , Dec. 8, 2016  Agenovir Corporation, a ... novel antiviral therapeutics, today announced that it appointed ... officer and a member of the board of ... executive with a deep background in both founding ... founder of Agenovir, co-president of Chan Zuckerberg  Biohub ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio ... the first national #QuackGivesBack campaign which supported local breast cancer organizations during National ... Quack Gives Back initiative, and we’re very pleased with the participation ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental ... Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related ... and prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it had joined the Pharmaceutical ... a non-profit organization to unite pharmaceutical and healthcare companies that share a vision ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an ... around the greater Phoenix metropolitan region, is announcing a charity event to provide ... the Homeless Youth Connection is to promote community awareness of the ongoing needs ...
Breaking Medicine News(10 mins):